Evolent Health (EVH) Stock Forecast, Price Target & Predictions
EVH Stock Forecast
Evolent Health stock forecast is as follows: an average price target of $44.00 (represents a 46.13% upside from EVH’s last price of $30.11) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
EVH Price Target
The average price target for Evolent Health (EVH) is $44.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $51.00 to $33.00. This represents a potential 46.13% upside from EVH's last price of $30.11.
EVH Analyst Ratings
According to 5 Wall Street analysts, Evolent Health's rating consensus is 'Buy'. The analyst rating breakdown for EVH stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Evolent Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 09, 2024 | Jailendra Singh | Truist Financial | $33.00 | $20.87 | 58.12% | 9.60% |
| Jun 05, 2024 | Sean Dodge | RBC Capital | $42.00 | $22.04 | 90.56% | 39.49% |
| May 14, 2024 | Jailendra Singh | Truist Financial | $28.00 | $23.75 | 17.89% | -7.01% |
| Apr 17, 2024 | Jessica Tassan | Piper Sandler | $51.00 | $29.60 | 72.30% | 69.38% |
| Mar 28, 2024 | Richard Close | Canaccord Genuity | $44.00 | $32.73 | 34.43% | 46.13% |
| Aug 03, 2022 | - | BTIG | $50.00 | $35.21 | 42.01% | 66.06% |
| May 09, 2022 | - | Canaccord Genuity | $45.00 | $26.91 | 67.22% | 49.45% |
The latest Evolent Health stock forecast, released on Aug 09, 2024 by Jailendra Singh from Truist Financial, set a price target of $33.00, which represents a 58.12% increase from the stock price at the time of the forecast ($20.87), and a 9.60% increase from EVH last price ($30.11).
Evolent Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 5 |
| Avg Price Target | - | $33.00 | $39.60 |
| Last Closing Price | $30.11 | $30.11 | $30.11 |
| Upside/Downside | -100.00% | 9.60% | 31.52% |
In the current month, the average price target of Evolent Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Evolent Health's last price of $30.11. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 19, 2024 | JMP Securities | Underperform | Underperform | Hold |
| Aug 19, 2024 | Stephens | Market Outperform | Market Outperform | Hold |
| Jun 05, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Apr 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Mar 28, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Feb 23, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Feb 23, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Oct 11, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 03, 2022 | BTIG | Buy | Buy | Hold |
| May 09, 2022 | Canaccord Genuity | Buy | Buy | Hold |
Evolent Health's last stock rating was published by JMP Securities on Aug 19, 2024. The company gave EVH a "Underperform" rating, the same as its previous rate.
Evolent Health Financial Forecast
Evolent Health Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $427.69M | $382.43M | $352.58M | $319.94M | $297.06M | $248.36M | $222.47M | $222.06M | $215.07M | $271.92M | $264.59M | $238.63M | $247.28M | $236.53M | $220.14M |
| Avg Forecast | $927.53M | $902.70M | $868.60M | $848.69M | $765.65M | $744.52M | $732.91M | $713.19M | $663.50M | $627.25M | $636.75M | $600.83M | $542.45M | $509.38M | $460.71M | $434.35M | $372.93M | $356.76M | $298.79M | $286.78M | $233.94M | $226.00M | $216.56M | $212.79M | $261.66M | $263.78M | $241.17M | $238.60M | $233.63M | $217.90M |
| High Forecast | $938.60M | $913.47M | $878.96M | $858.81M | $774.78M | $753.40M | $741.65M | $721.70M | $671.41M | $633.13M | $644.35M | $608.00M | $548.91M | $515.46M | $466.21M | $439.53M | $377.38M | $361.02M | $303.29M | $291.10M | $237.47M | $229.41M | $219.82M | $215.99M | $265.61M | $267.76M | $244.80M | $242.19M | $237.15M | $221.19M |
| Low Forecast | $915.38M | $890.87M | $857.21M | $837.57M | $755.61M | $734.76M | $723.30M | $703.84M | $654.80M | $621.28M | $628.41M | $592.96M | $539.68M | $502.71M | $454.67M | $428.65M | $368.04M | $352.09M | $295.50M | $283.62M | $231.36M | $223.51M | $214.18M | $210.44M | $258.78M | $260.88M | $238.51M | $235.97M | $231.06M | $215.50M |
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 9 | 15 | 9 | 9 | 16 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | 1.03% | 0.99% | 1.07% | 1.04% | 1.06% | 0.98% | 1.03% | 1.01% | 1.04% | 1.00% | 0.99% | 1.04% | 1.01% | 1.01% |
Evolent Health's average Quarter revenue forecast for Jun 23 based on 5 analysts is $460.71M, with a low forecast of $454.67M, and a high forecast of $466.21M. EVH's average Quarter revenue forecast represents a 7.72% increase compared to the company's last Quarter revenue of $427.69M (Mar 23).
Evolent Health EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 9 | 15 | 9 | 9 | 16 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-20.96M | $-24.70M | $-37.43M | $-1.72M | $-23.95M | $13.75M | $19.28M | $15.42M | $8.42M | $12.17M | $12.49M | $8.16M | $-14.73M | $-185.35M | $-56.06M | $-200.02M | $-7.33M |
| Avg Forecast | $13.77M | $13.40M | $12.89M | $12.60M | $11.37M | $11.05M | $10.88M | $10.59M | $9.85M | $9.31M | $9.45M | $24.93M | $8.05M | $7.56M | $6.84M | $22.67M | $5.54M | $10.65M | $13.74M | $4.26M | $3.47M | $3.35M | $3.21M | $20.61M | $3.88M | $3.92M | $3.58M | $-51.75M | $3.47M | $3.23M |
| High Forecast | $13.93M | $13.56M | $13.05M | $12.75M | $11.50M | $11.18M | $11.01M | $10.71M | $9.97M | $9.40M | $9.57M | $29.92M | $8.15M | $7.65M | $6.92M | $27.20M | $5.60M | $12.78M | $16.48M | $4.32M | $3.53M | $3.41M | $3.26M | $24.73M | $3.94M | $3.97M | $3.63M | $-41.40M | $3.52M | $3.28M |
| Low Forecast | $13.59M | $13.23M | $12.73M | $12.43M | $11.22M | $10.91M | $10.74M | $10.45M | $9.72M | $9.22M | $9.33M | $19.95M | $8.01M | $7.46M | $6.75M | $18.13M | $5.46M | $8.52M | $10.99M | $4.21M | $3.43M | $3.32M | $3.18M | $16.48M | $3.84M | $3.87M | $3.54M | $-62.10M | $3.43M | $3.20M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.77% | -3.61% | -1.65% | -0.31% | -2.25% | 1.00% | 4.53% | 4.44% | 2.51% | 3.79% | 0.61% | 2.10% | -3.76% | -51.77% | 1.08% | -57.67% | -2.27% |
3 analysts predict EVH's average Quarter EBITDA for Sep 22 to be $10.65M, with a high of $12.78M and a low of $8.52M. This is -22.54% lower than Evolent Health's previous annual EBITDA (Jun 22) of $13.75M.
Evolent Health Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 9 | 15 | 9 | 9 | 16 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-33.20M | $-41.41M | $-19.98M | $-11.35M | $2.12M | $-4.13M | $-5.35M | $3.05M | $-13.04M | $-9.11M | $-9.81M | $-14.63M | $-37.35M | $-203.52M | $-78.75M | $-198.10M | $-25.52M |
| Avg Forecast | $50.04M | $50.49M | $48.91M | $48.69M | $50.62M | $48.39M | $45.29M | $44.21M | $37.83M | $32.32M | $27.43M | $-19.58M | $19.09M | $11.81M | $17.77M | $-17.80M | $11.21M | $-16.50M | $-5.05M | $-229.38K | $955.70K | $-3.93M | $-5.57M | $-16.18M | $-5.30M | $-5.05M | $-11.36M | $-72.69M | $-4.13M | $-14.31M |
| High Forecast | $50.82M | $51.28M | $49.67M | $49.44M | $51.41M | $49.14M | $45.99M | $44.90M | $38.42M | $44.58M | $27.86M | $-15.66M | $22.57M | $12.00M | $18.04M | $-14.24M | $11.38M | $-13.20M | $-4.04M | $-226.09K | $974.41K | $-3.88M | $-5.49M | $-12.95M | $-5.23M | $-4.97M | $-11.20M | $-58.16M | $-4.07M | $-14.10M |
| Low Forecast | $49.19M | $49.63M | $48.07M | $47.86M | $49.76M | $47.57M | $44.52M | $43.46M | $37.19M | $24.52M | $26.97M | $-23.50M | $17.36M | $11.61M | $17.46M | $-21.36M | $11.02M | $-19.79M | $-6.06M | $-233.87K | $942.01K | $-4.01M | $-5.68M | $-19.42M | $-5.41M | $-5.15M | $-11.59M | $-87.23M | $-4.21M | $-14.59M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.81% | -2.33% | 1.12% | -1.01% | -0.13% | 0.82% | 23.32% | 3.19% | 3.32% | 1.63% | 0.61% | 2.76% | 7.40% | 17.91% | 1.08% | 47.98% | 1.78% |
Evolent Health's average Quarter net income forecast for Dec 22 is $11.21M, with a range of $11.02M to $11.38M. EVH's average Quarter net income forecast represents a 427.88% increase compared to the company's last Quarter net income of $2.12M (Sep 22).
Evolent Health SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 9 | 15 | 9 | 9 | 16 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $96.57M | $90.39M | $89.73M | $82.86M | $68.52M | $58.95M | $58.93M | $66.92M | $51.29M | $42.70M | $58.59M | $86.45M | $77.08M | $68.66M | $78.36M | $83.60M | $93.61M |
| Avg Forecast | $258.06M | $251.15M | $241.66M | $236.12M | $213.02M | $207.14M | $203.91M | $198.43M | $184.60M | $174.52M | $177.16M | $116.98M | $150.92M | $141.72M | $128.18M | $106.34M | $103.76M | $64.88M | $64.85M | $79.79M | $65.09M | $62.88M | $60.25M | $96.68M | $72.80M | $73.39M | $67.10M | $72.34M | $65.00M | $60.63M |
| High Forecast | $261.14M | $254.15M | $244.55M | $238.94M | $215.56M | $209.61M | $206.34M | $200.79M | $186.80M | $176.15M | $179.27M | $140.37M | $152.72M | $143.41M | $129.71M | $127.61M | $104.99M | $77.86M | $77.82M | $80.99M | $66.07M | $63.83M | $61.16M | $116.01M | $73.90M | $74.50M | $68.11M | $86.80M | $65.98M | $61.54M |
| Low Forecast | $254.68M | $247.86M | $238.50M | $233.03M | $210.23M | $204.43M | $201.24M | $195.83M | $182.18M | $172.85M | $174.84M | $93.58M | $150.15M | $139.86M | $126.50M | $85.07M | $102.40M | $51.91M | $51.88M | $78.91M | $64.37M | $62.19M | $59.59M | $77.34M | $72.00M | $72.58M | $66.36M | $57.87M | $64.29M | $59.96M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.68% | 0.71% | 0.84% | 0.80% | 1.06% | 0.91% | 0.74% | 1.03% | 0.82% | 0.71% | 0.61% | 1.19% | 1.05% | 1.02% | 1.08% | 1.29% | 1.54% |
Evolent Health's average Quarter SG&A projection for Dec 23 is $150.92M, based on 8 Wall Street analysts, with a range of $150.15M to $152.72M. The forecast indicates a 56.29% rise compared to EVH last annual SG&A of $96.57M (Sep 23).
Evolent Health EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 9 | 15 | 9 | 9 | 16 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.30 | $-0.37 | $-0.19 | $-0.11 | $0.02 | $-0.05 | $-0.06 | $0.03 | $-0.15 | $-0.11 | $-0.12 | $-0.17 | $-0.44 | $-2.38 | $-0.92 | $-2.36 | $-0.30 |
| Avg Forecast | $0.44 | $0.44 | $0.43 | $0.42 | $0.44 | $0.42 | $0.39 | $0.39 | $0.33 | $0.28 | $0.24 | $0.22 | $0.17 | $0.10 | $0.15 | $0.17 | $0.10 | $0.12 | $0.05 | $-0.00 | $0.01 | $-0.03 | $-0.05 | $-0.07 | $-0.05 | $-0.04 | $-0.10 | $-0.13 | $-0.04 | $-0.12 |
| High Forecast | $0.44 | $0.45 | $0.43 | $0.43 | $0.45 | $0.43 | $0.40 | $0.39 | $0.33 | $0.39 | $0.24 | $0.22 | $0.20 | $0.10 | $0.16 | $0.17 | $0.10 | $0.12 | $0.05 | $-0.00 | $0.01 | $-0.03 | $-0.05 | $-0.06 | $-0.05 | $-0.04 | $-0.10 | $-0.13 | $-0.04 | $-0.12 |
| Low Forecast | $0.43 | $0.43 | $0.42 | $0.42 | $0.43 | $0.41 | $0.39 | $0.38 | $0.32 | $0.21 | $0.24 | $0.21 | $0.15 | $0.10 | $0.15 | $0.17 | $0.10 | $0.12 | $0.05 | $-0.00 | $0.01 | $-0.03 | $-0.05 | $-0.07 | $-0.05 | $-0.04 | $-0.10 | $-0.13 | $-0.04 | $-0.13 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.91% | -2.39% | -1.11% | -1.13% | 0.17% | -0.94% | 29.90% | 4.15% | 4.37% | 2.26% | 1.85% | 3.68% | 10.00% | 24.02% | 7.02% | 65.56% | 2.40% |
According to 4 Wall Street analysts, Evolent Health's projected average Quarter EPS for Dec 22 is $0.10, with a low estimate of $0.10 and a high estimate of $0.10. This represents a 388.58% increase compared to EVH previous annual EPS of $0.02 (Sep 22).
Evolent Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HCAT | Health Catalyst | $8.44 | $29.25 | 246.56% | Buy |
| DH | Definitive Healthcare | $4.44 | $9.92 | 123.42% | Hold |
| CERT | Certara | $10.95 | $21.75 | 98.63% | Hold |
| FORA | Forian | $2.28 | $4.50 | 97.37% | Buy |
| PRVA | Privia Health Group | $18.95 | $33.82 | 78.47% | Buy |
| SLP | Simulations Plus | $32.50 | $56.00 | 72.31% | Buy |
| EVH | Evolent Health | $30.11 | $44.00 | 46.13% | Buy |
| CMAX | CareMax | $2.04 | $2.60 | 27.45% | Hold |
| HQY | HealthEquity | $78.23 | $97.00 | 23.99% | Buy |
EVH Forecast FAQ
Is Evolent Health a good buy?
Yes, according to 5 Wall Street analysts, Evolent Health (EVH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of EVH's total ratings.
What is EVH's price target?
Evolent Health (EVH) average price target is $44 with a range of $33 to $51, implying a 46.13% from its last price of $30.11. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Evolent Health stock go up soon?
According to Wall Street analysts' prediction for EVH stock, the company can go up by 46.13% (from the last price of $30.11 to the average price target of $44), up by 69.38% based on the highest stock price target, and up by 9.60% based on the lowest stock price target.
Can Evolent Health stock reach $50?
EVH's highest twelve months analyst stock price target of $51 supports the claim that Evolent Health can reach $50 in the near future.
What are Evolent Health's analysts' financial forecasts?
Evolent Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.96B (high $2.99B, low $2.92B), average EBITDA is $43.89M (high $44.41M, low $43.31M), average net income is $188.52M (high $191.44M, low $185.3M), average SG&A $822.5M (high $832.31M, low $811.72M), and average EPS is $1.64 (high $1.67, low $1.62). EVH's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.55B (high $3.59B, low $3.5B), average EBITDA is $52.66M (high $53.29M, low $51.97M), average net income is $198.14M (high $201.21M, low $194.76M), average SG&A $987M (high $998.77M, low $974.07M), and average EPS is $1.73 (high $1.75, low $1.7).
Did the EVH's actual financial results beat the analysts' financial forecasts?
Based on Evolent Health's last annual report (Dec 2022), the company's revenue was $1.35B, beating the average analysts forecast of $1.32B by 2.79%. Apple's EBITDA was $7.36M, missing the average prediction of $34.18M by -78.47%. The company's net income was $-18.701M, beating the average estimation of $-10.565M by 77.01%. Apple's SG&A was $269.27M, missing the average forecast of $313.28M by -14.05%. Lastly, the company's EPS was $-0.2, missing the average prediction of $0.263 by -176.09%. In terms of the last quarterly report (Mar 2023), Evolent Health's revenue was $427.69M, missing the average analysts' forecast of $434.35M by -1.53%. The company's EBITDA was $-37.432M, missing the average prediction of $22.67M by -265.15%. Evolent Health's net income was $-19.982M, beating the average estimation of $-17.8M by 12.26%. The company's SG&A was $89.73M, missing the average forecast of $106.34M by -15.63%. Lastly, the company's EPS was $-0.19, missing the average prediction of $0.171 by -211.27%